Table 2.
Comparison of Clinicopathological Characteristics Between Histological Grade I + II and Grade III Groups
| Characteristics | Training Set (n=560) | P | Test Set (n=140) | P | ||
|---|---|---|---|---|---|---|
| Grade I+II (n=381) | Grade III (n=179) | Grade I+II (n=95) | Grade III (n=45) | |||
Age (Year,  ) |
48.88±10.18 | 49.13±10.91 | 0.168a | 49.12±8.85 | 47.73±10.95 | 0.075a |
| Menstrual status (%) | ||||||
| Premenopausal | 214 (56.17) | 92 (51.40) | 0.290b | 61(64.21) | 28 (62.22) | 0.819b |
| Postmenopausal | 167 (43.83) | 87 (48.60) | 34 (35.79) | 17 (37.78) | ||
| Location of disease (%) | ||||||
| Left breast | 183 (48.03) | 86 (48.04) | 0.998b | 48 (50.52) | 24 (53.33) | 0.756b |
| Right breast | 198 (51.97) | 93 (51.96) | 47 (49.47) | 21 (46.67) | ||
| Tumor size [M (Q1, Q3)]mm | 20 (15,26) | 25 (19,34) | <0.001c | 20 (14,26) | 23 (19,28) | <0.001c |
| HER2 status (%) | ||||||
| Positive | 87 (22.83) | 58 (32.40) | 0.016b | 20 (21.05) | 19 (42.22) | 0.009b |
| Negative | 294 (77.17) | 121 (67.60) | 75 (78.95) | 26 (57.78) | ||
| ER status (%) | ||||||
| <10% | 57 (14.96) | 91 (50.84) | <0.001b | 16 (16.84) | 25 (55.56) | <0.001b |
| ≥10% | 324 (85.04) | 88 (49.16) | 79 (83.16) | 20 (44.44) | ||
| PR status (%) | ||||||
| ≤20% | 150 (39.37) | 130 (72.63) | <0.001b | 40 (42.11) | 35 (77.78) | <0.001b |
| >20% | 231 (60.63) | 49 (27.37) | 55 (57.89) | 10 (22.22) | ||
| Ki-67 (%) | ||||||
| ≤20% | 197 (51.71) | 19 (10.61) | <0.001b | 52 (54.74) | 6 (13.33) | <0.001b |
| >20% | 184 (48.29) | 160 (89.39) | 43 (45.26) | 39 (86.67) | ||
Notes: aindependent-sample t-test; bchi-square test; cMann-Whitney U-test. The bold values presented indicate statistically significant p-values.
Abbreviations: HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor.